PTO/SB/08s (08-03) Approved for use through 07/31/2008, OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

> Remove Pages, Columns, Lines where

Figures Appear

Relevant Passages or Relevant

Under the Paperwork Reduction Act of 1995, no persons are required to resp to a collection of information unless it contains a valid OMB control number.

	Application Number	- 1		
	Filing Date		2006-02-03	
INFORMATION DISCLOSURE	First Named Inventor	Kazul	uhiro YANAGISAWA	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit			
(Not for Submission and a set of the first)	Examiner Name			
	Attorney Docket Number	r	Q92943	

U.S.PATENTS

Name of Patentee or Applicant

of cited Document

Code¹ Issue Date

Examiner Cite

Initial* No Patent Number

	1										
If you wis	h to a	l dd additional U.S. Pater							Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number			of sited Desument			ges,Columns,Lines where elevant Passages or Relevant gures Appear			
	1	20030134943	A1	2003-0	7-17	RHONE-POU	LENC CHIMIE				
If you wis	h to a	dd additional U.S. Publi		p				d buttor			
				FOREIG	SN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code²	Kind Code4		Name of Patentee or Applicant of cited Document		where Rel	or Relevant	70
	1	2002363295	JP		A	2002-12-18	SUMITOMO RUBE INDUSTRIES, LTD				
	2	1283219	EP		A2	2003-12-02	BRIDGESTONE C	ORP.			
	3	2003520880	JP		A	2003-07-08	RHONE-POULEN	-			

			Application Number				1			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Filing Date				2006-02-03				
		First Named Inventor Kazuh		nhiro YANAGISAWA						
		Art Unit								
(Not for Submission ander or or it is say			Examiner Name							
				Attorney Docket Number			r	Q92943		
	4	200341055	JP		A	2003-02-13	Π,	BRIDGESTONE CORP.		T

Examiner Initials*	Na	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, cetalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
	1		ı					

If you wish to add additional non-patent literature document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS

If you wish to add additional Foreign Patent Document citation information please click the Add button

EYAMINED SIGNATURE Examiner Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

1 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

		Application Number			
	Filing Date		2006-02-03		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Kazul		uhiro YANAGISAWA	
		Art Unit			
(,	Examiner Name			
		Attorney Docket Numb	er	Q92943	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

√ None

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.Sc. 122 and 37 CFR 1.4. This collection is estimated to set invote to complete, including gathering, preparing and submitting the complete of the confidence of the confi

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.